PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
34.37%
Net income growth above 1.5x AXSM's 19.26%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
0.63%
Some D&A expansion while AXSM is negative at -0.70%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
-79.79%
Negative yoy SBC while AXSM is 5.59%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-121.40%
Negative yoy working capital usage while AXSM is 0.00%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-200.00%
Both negative yoy AP, with AXSM at -56.31%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-91.42%
Negative yoy usage while AXSM is 100.00%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
2.52%
Some yoy increase while AXSM is negative at -19.79%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-18.12%
Negative yoy CFO while AXSM is 25.25%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
100.00%
CapEx growth of 100.00% while AXSM is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Investing outflow well above AXSM's 96.15%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy issuance while AXSM is 66.07%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.